Does Cigna Cover Weight Loss Injections? Policy Breakdown and Authorization Strategies

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Cigna covers semaglutide and tirzepatide injections for type 2 diabetes on most commercial plans but excludes coverage for weight loss alone in 94% of employer-sponsored policies as of 2026
• Prior authorization requires documented BMI above 30 (or 27 with comorbidities), failed lifestyle intervention attempts, and specific diagnostic codes that vary by plan tier
• The average Cigna member pays $850-$1,200 monthly out-of-pocket for brand-name weight-loss injections when coverage is denied, compared to $179-$299 for compounded alternatives
• Cigna's medical policy 0591 explicitly excludes Wegovy and Saxenda from most formularies unless the employer purchases a separate obesity rider, which only 6% of Cigna groups elected in 2025

Direct answer (40-60 words)

Cigna covers GLP-1 receptor agonist injections (semaglutide, tirzepatide, liraglutide) when prescribed for FDA-approved diabetes indications. Coverage for weight loss alone requires an employer-purchased obesity benefit rider, which most Cigna plans do not include. Without the rider, members pay full retail price or use compounded alternatives at 70-85% lower cost.

Table of contents

1. The coverage reality most articles misrepresent
2. How Cigna categorizes weight-loss medications in 2026
3. The three-tier formulary structure and where GLP-1s land
4. Prior authorization requirements: the complete checklist
5. What the obesity rider actually covers (and what it costs employers)
6. The diagnostic code strategy that improves approval rates
7. When Cigna denies coverage: the appeal process that works
8. Self-pay pricing versus compounded alternatives
9. The Medicare Advantage exception (and why it matters)
10. Decision tree: your coverage pathway based on plan type
11. FAQ
12. Sources

The coverage reality most articles misrepresent

Most insurance coverage guides published between 2023 and 2025 claim "Cigna covers Ozempic and Mounjaro for weight loss with prior authorization." This is categorically false for 94% of Cigna commercial plans.

The confusion stems from three sources:

Error 1: Conflating diabetes coverage with obesity coverage. Cigna covers semaglutide (Ozempic, Rybelsus) and tirzepatide (Mounjaro) when prescribed for type 2 diabetes mellitus. The FDA approved these drugs for diabetes first, and they remain on-formulary for that indication. When a patient happens to lose weight while being treated for diabetes, that weight loss is a documented side effect, not the primary indication. The claim is processed under the diabetes diagnosis code (E11.9), not obesity (E66.01).

Error 2: Assuming Wegovy coverage equals Ozempic coverage. Wegovy is FDA-approved specifically for chronic weight management. It contains the same active ingredient as Ozempic (semaglutide) but at a higher dose and with a different FDA indication. Cigna's medical policy 0591 (Obesity Interventions, revised January 2026) explicitly lists Wegovy as "not medically necessary" unless the plan includes an optional obesity rider. Ozempic remains covered for diabetes regardless of the rider.

Error 3: Extrapolating from Medicare Advantage to commercial plans. Some Cigna Medicare Advantage plans added limited obesity drug coverage in 2024 following CMS guidance changes. This coverage does NOT apply to employer-sponsored commercial plans, individual marketplace plans, or Cigna's self-funded administrative services. The Medicare Advantage exception is plan-specific and requires separate prior authorization criteria.

The pattern we observe across FormBlends intake data from 2,400+ patients who attempted Cigna prior authorization between January 2025 and March 2026: 11% approval rate for weight-loss-only indications on commercial plans without an obesity rider, 89% approval rate for diabetes indications with documented A1C above 7.0%, and 34% approval rate on Medicare Advantage plans with the obesity benefit.

How Cigna categorizes weight-loss medications in 2026

Cigna uses a four-category system for obesity and metabolic medications, updated quarterly in the National Pharmacy Benefit Management formulary:

Category 1: Diabetes medications with weight-loss effects (formulary-covered). Includes semaglutide (Ozempic, Rybelsus), tirzepatide (Mounjaro), dulaglutide (Trulicity), and liraglutide (Victoza). Covered when prescribed for type 2 diabetes with prior authorization. The authorization requires documented A1C, failed metformin trial, and diabetes diagnosis code. Weight loss occurring during diabetes treatment is documented but not the basis for coverage.

Category 2: FDA-approved obesity medications (rider-dependent). Includes semaglutide 2.4 mg (Wegovy), liraglutide 3.0 mg (Saxenda), and the discontinued setmelanotide (Imcivree). Covered only if the employer purchased the obesity rider. The rider costs employers an additional $40-$80 per member per month (PMPM) regardless of utilization, which is why adoption remains below 6% of Cigna commercial groups.

Category 3: Off-label diabetes medications for weight loss (not covered). This is where most denials occur. If a provider prescribes Ozempic or Mounjaro using an obesity diagnosis code (E66.01, E66.09, E66.8) without a documented diabetes diagnosis, Cigna's automated claims system flags it as off-label use and denies coverage. The denial letter typically states "not medically necessary for the diagnosis provided."

Category 4: Compounded GLP-1 medications (never covered). Compounded semaglutide and tirzepatide are not FDA-approved products and are explicitly excluded from all Cigna pharmacy benefits. Patients using compounded medications pay out-of-pocket regardless of diagnosis. This is standard across all major insurers, not Cigna-specific.

The key insight: the same molecule (semaglutide) has different coverage rules depending on the brand name, dose, and diagnosis code submitted. A prescription for "Ozempic 1 mg weekly for type 2 diabetes" is processed differently than "Wegovy 2.4 mg weekly for obesity," even though both are semaglutide.

The three-tier formulary structure and where GLP-1s land

Cigna commercial plans use a five-tier formulary structure for most benefits, but GLP-1 medications land almost exclusively in tiers 3, 4, or specialty:

Tier	Copay structure	GLP-1 placement	Prior auth required
Tier 1 (generic preferred)	$10-$25	None (no generic GLP-1s exist)	No
Tier 2 (brand preferred)	$40-$75	None	Rare
Tier 3 (non-preferred brand)	$75-$150	Rybelsus (oral semaglutide) on some plans	Yes
Tier 4 (specialty oral)	20-30% coinsurance	Occasionally Rybelsus	Yes
Specialty (injectable)	25-40% coinsurance, $200-$500 max	Ozempic, Wegovy, Mounjaro, Saxenda, Trulicity	Always

Most Cigna plans place all injectable GLP-1s in the specialty tier, which means the member pays a percentage of the drug's list price rather than a flat copay. The 2026 list prices:

• Ozempic: $968.52 per pen (4 doses)
• Wegovy: $1,349.02 per pen (4 doses)
• Mounjaro: $1,023.04 per pen (4 doses)
• Saxenda: $1,427.36 per pen (30-day supply)

At 30% coinsurance, a member pays $290-$405 monthly even when the drug is covered. At 40% coinsurance (common in high-deductible health plans), the monthly cost is $387-$571.

The specialty tier also triggers a separate deductible on many plans. If your plan has a $3,000 medical deductible and a $500 specialty pharmacy deductible, you pay 100% of the drug cost until you've spent $500 on specialty medications in the calendar year, then the coinsurance percentage applies.

Prior authorization requirements: the complete checklist

Cigna's prior authorization form for GLP-1 medications (form PA-0591-2026, effective January 2026) requires nine data points. Missing any single element triggers an automatic denial with a request for additional information, which delays approval by 10-14 business days.

The nine required elements:

1. Primary diagnosis code. E11.9 (type 2 diabetes mellitus without complications) is the most commonly approved code. E66.01 (morbid obesity due to excess calories) is approved only on plans with the obesity rider.

1. Documented BMI within the past 90 days. Must be above 30 kg/m², or above 27 kg/m² with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). The BMI must be calculated from a measured height and weight, not patient-reported.

1. A1C result within the past 180 days (diabetes indications only). Cigna requires A1C above 7.0% to justify GLP-1 therapy. If A1C is below 7.0%, the authorization is denied with the rationale "diabetes is adequately controlled on current therapy."

1. Failed trial of metformin or documented contraindication. The trial must be at least 90 days at a dose of 1,000 mg daily or higher, with documented inadequate response (A1C remained above 7.0%) or intolerable side effects. If the patient has a contraindication (renal impairment with eGFR below 30, history of lactic acidosis), the provider must document it with a specific ICD-10 code.

1. Failed trial of a sulfonylurea or DPP-4 inhibitor (required on some plans). This is plan-specific. Cigna's step-therapy protocol on many employer plans requires a trial of metformin plus one additional oral agent before approving a GLP-1. The second agent must be tried for at least 60 days.

1. Documented lifestyle intervention attempt. This is the vaguest requirement and the most common reason for appeal. Cigna requires "evidence of participation in a structured weight management or diabetes self-management program within the past 12 months." Acceptable documentation includes enrollment in a registered dietitian program, completion of a diabetes education class, or participation in a medically supervised weight-loss program. A provider's note stating "patient reports diet and exercise" is not sufficient.

1. Prescriber specialty or attestation. Cigna prefers that GLP-1s be prescribed by an endocrinologist, obesity medicine specialist, or primary care provider with documented experience in diabetes management. Prescriptions from nurse practitioners or physician assistants may require additional attestation that the prescription was reviewed by a supervising physician.

1. Requested dose and duration. The prior authorization must specify the exact dose (e.g., "semaglutide 1 mg subcutaneous weekly") and the duration of therapy (typically 90 days for the initial authorization, 365 days for renewals). Requests for doses above the FDA-approved maximum are automatically denied.

1. Pharmacy selection. GLP-1 medications must be filled at a Cigna-designated specialty pharmacy (Accredo is the default for most plans). Prescriptions sent to retail pharmacies are rejected even if prior authorization is approved.

The approval timeline: 3 business days for urgent requests (defined as "patient currently on therapy and out of medication"), 15 business days for standard requests. In practice, most approvals take 8-12 business days because the automated system flags incomplete submissions and routes them to manual review.

What the obesity rider actually covers (and what it costs employers)

The Cigna obesity benefit rider (officially the "Comprehensive Weight Management Rider") is an optional add-on that employers can purchase for their group health plan. As of 2026, 6.2% of Cigna commercial groups have elected the rider, up from 3.1% in 2024 (Cigna internal enrollment data reported in their Q4 2025 investor presentation).

What the rider covers:

• FDA-approved obesity medications including Wegovy, Saxenda, and Contrave (naltrexone/bupropion)
• Bariatric surgery (gastric bypass, sleeve gastrectomy, adjustable gastric banding) with prior authorization
• Nutritional counseling (up to 26 visits per year with a registered dietitian)
• Behavioral therapy for obesity (up to 12 sessions per year)

What the rider does NOT cover:

• Compounded semaglutide or tirzepatide
• Off-label use of diabetes medications for weight loss (Ozempic, Mounjaro)
• Over-the-counter weight-loss supplements or meal replacements
• Cosmetic procedures following weight loss (skin removal surgery)

The cost structure: employers pay an additional $52-$78 PMPM for the rider, depending on group size and geographic region. For a 500-employee group, the annual cost is $312,000-$468,000 regardless of how many employees use the benefit. This is why adoption remains low. Employers compare the guaranteed cost against the expected utilization (typically 2-4% of covered lives) and conclude the ROI is negative unless obesity prevalence in their workforce is exceptionally high.

The member cost-sharing: even with the rider, members pay specialty-tier coinsurance (25-40%) for obesity medications. The rider changes the coverage determination (from "not covered" to "covered with prior authorization") but does not change the tier placement. A member on a plan with the rider still pays $300-$500 monthly for Wegovy.

The pattern we observe in FormBlends intake data: patients who work for self-insured employers with more than 5,000 employees are 3.2 times more likely to have the obesity rider than patients at small employers (under 500 employees). Large employers can spread the PMPM cost across a bigger risk pool and are more likely to have dedicated benefits teams that evaluate optional riders.

The diagnostic code strategy that improves approval rates

The single biggest variable in Cigna prior authorization outcomes is the diagnosis code submitted on the claim. Two codes have dramatically different approval rates even when the clinical picture is identical:

E11.9 (type 2 diabetes mellitus without complications): 89% approval rate for semaglutide and tirzepatide on commercial plans without the obesity rider, based on analysis of 1,847 prior authorization requests submitted by FormBlends partner providers between January 2025 and March 2026.

E66.01 (morbid obesity due to excess calories): 11% approval rate on plans without the obesity rider, 76% approval rate on plans with the rider.

The strategic implication: if a patient has both obesity and prediabetes (A1C 5.7-6.4%), the provider has discretion in which diagnosis to emphasize. Submitting the prediabetes code (R73.03) typically results in a request for additional information and a recommendation to try lifestyle modification first. Submitting the diabetes code (E11.9) after documenting that A1C has crossed the 6.5% threshold results in faster approval.

This is not fraud. It is accurate coding based on clinical findings. The ethical boundary is clear: the diagnosis must be supported by lab results and clinical documentation. Submitting a diabetes code when the patient's A1C is 5.4% is insurance fraud. Submitting a diabetes code when the patient's A1C is 7.2% is appropriate even if weight loss is the patient's primary goal.

The comorbidity multiplier: Cigna's authorization algorithm gives additional weight to claims that include secondary diagnosis codes for obesity-related complications. A claim submitted with E11.9 (diabetes) plus I10 (hypertension) plus E78.5 (hyperlipidemia) has a higher approval probability than E11.9 alone, even though the medication is the same. The system is designed to prioritize patients with multiple metabolic risk factors.

What most providers get wrong: submitting only the obesity code on the initial request, receiving a denial, then appealing with the diabetes code. This adds 30-45 days to the approval timeline. The optimal strategy is to submit the diabetes code on the first request if the patient meets diagnostic criteria, even if obesity is the patient's primary concern.

When Cigna denies coverage: the appeal process that works

Cigna's denial letter includes a standard appeals process with three levels. The success rate at each level differs dramatically:

Level 1: Peer-to-peer review (18% overturn rate). The prescribing provider requests a phone call with a Cigna medical director to discuss the clinical rationale. The call is scheduled within 5 business days. The medical director is typically a board-certified physician in internal medicine or endocrinology. The conversation is not adversarial but it is scripted. The medical director has a checklist of coverage criteria and will ask specific questions about metformin trials, A1C results, and lifestyle interventions. If the provider can document that all criteria were met but the automated system misread the submission, the denial is overturned. If the criteria genuinely were not met, the denial stands.

Level 2: External medical review (34% overturn rate). The patient or provider submits a written appeal with additional clinical documentation to an independent review organization (IRO) contracted by Cigna. The IRO physician reviews the case against evidence-based clinical guidelines, not just Cigna's internal policies. This is where coverage denials based on "not medically necessary" are most often overturned. The review takes 30-45 days. The IRO decision is binding on Cigna.

Level 3: State insurance department complaint (61% overturn rate, but only for specific denial reasons). If the denial is based on a coverage exclusion written into the plan document (e.g., "obesity medications are excluded"), the state insurance department cannot override it. If the denial is based on an incorrect application of medical necessity criteria, the state can order Cigna to cover the medication. This process takes 60-90 days and requires the patient to file a formal complaint with their state's department of insurance.

The appeal strategy that works: most successful appeals include three elements that were missing from the initial prior authorization:

1. A detailed letter from the prescribing provider explaining why this specific patient requires this specific medication. The letter should reference published clinical trial data (e.g., "This patient's clinical profile matches the inclusion criteria for the STEP 1 trial, where semaglutide 2.4 mg produced a mean weight loss of 14.9% at 68 weeks, compared to 2.4% with placebo" (Wilding et al., New England Journal of Medicine, 2021)).

1. Documentation of failed alternatives. If the patient tried phentermine, orlistat, or naltrexone/bupropion and experienced inadequate weight loss or intolerable side effects, document it with dates and specific outcomes. Cigna's medical policy states that GLP-1s should be reserved for patients who have failed other interventions, so proving failure strengthens the appeal.

1. A statement of medical necessity tied to a specific health risk. Generic statements like "patient needs to lose weight for overall health" are weak. Specific statements like "patient's BMI of 38 combined with A1C of 7.8% places her at high risk for cardiovascular events, with a 10-year ASCVD risk score of 18% per the ACC/AHA calculator" are strong. The appeal should frame the medication as risk reduction, not cosmetic weight loss.

The timeline reality: even successful appeals add 45-90 days to the process. Most patients cannot wait that long, which is why 73% of patients who receive an initial denial switch to self-pay options rather than appealing (FormBlends intake survey data, n=1,247, January-December 2025).

Self-pay pricing versus compounded alternatives

When Cigna denies coverage or the patient decides not to appeal, the decision tree has two branches: pay retail price for brand-name medication or switch to a compounded alternative.

Retail pricing for brand-name GLP-1s (2026):

Medication	Monthly cost (cash price)	Manufacturer savings card	Net cost with card
Ozempic 2 mg weekly	$968.52	Up to $150/month off	$818.52
Wegovy 2.4 mg weekly	$1,349.02	Up to $500/month off (eligibility restrictions apply)	$849.02
Mounjaro 5-15 mg weekly	$1,023.04	Up to $550/month off	$473.04
Saxenda 3.0 mg daily	$1,427.36	Up to $200/month off	$1,227.36

Important restriction: manufacturer savings cards cannot be used in combination with government insurance (Medicare, Medicaid, Tricare) or when the medication is covered by the patient's commercial insurance. The cards are only valid for cash-pay patients or patients whose insurance denied coverage. If Cigna approved your prior authorization but you have high cost-sharing, you cannot use the savings card to reduce your copay.

Compounded semaglutide and tirzepatide pricing (2026):

Compounded GLP-1 medications are prepared by state-licensed compounding pharmacies using the same active pharmaceutical ingredient as brand-name products but without FDA review of the compounded formulation. They are legal to prescribe and dispense under the FDA's compounding guidance when the brand-name product is in shortage or when a patient has a documented clinical need for a customized formulation.

Compounded medication	Typical monthly cost	Dose range	Pharmacy source
Semaglutide (subcutaneous)	$249-$299	0.25 mg - 2.4 mg weekly	503B outsourcing facilities
Tirzepatide (subcutaneous)	$349-$449	2.5 mg - 15 mg weekly	503B outsourcing facilities
Semaglutide + B12 (subcutaneous)	$279-$329	0.25 mg - 2.4 mg weekly	503A compounding pharmacies

The cost difference is 70-85% lower than brand-name retail pricing and 40-65% lower than brand-name pricing with manufacturer savings cards. The clinical equivalence question is contested. Compounded semaglutide contains the same active ingredient but has not undergone the same stability testing, sterility validation, or bioequivalence studies as brand-name products. The FDA has issued warning letters to compounding pharmacies for potency failures and sterility violations, but the majority of 503B outsourcing facilities maintain clean inspection records.

FormBlends works exclusively with 503B outsourcing facilities that are registered with the FDA, inspected under current good manufacturing practices (cGMP), and provide third-party sterility and potency testing for each batch. This does not make compounded semaglutide FDA-approved, but it does reduce the quality-control risk compared to 503A pharmacies that compound on a per-prescription basis without batch testing.

The decision framework: patients choose compounded medications when (1) insurance denies coverage and retail pricing is unaffordable, (2) the manufacturer savings card is unavailable due to eligibility restrictions, or (3) the patient prefers a lower-cost option and accepts that compounded products are not FDA-reviewed. Patients choose brand-name medications when (1) insurance covers the medication with acceptable cost-sharing, (2) the manufacturer savings card reduces the price to a level comparable to compounded alternatives, or (3) the patient prioritizes FDA approval and is willing to pay the price premium.

The Medicare Advantage exception (and why it matters)

Cigna Medicare Advantage plans operate under different coverage rules than commercial plans because they are regulated by the Centers for Medicare & Medicaid Services (CMS) rather than state insurance departments and ERISA.

The 2024 CMS guidance change: in December 2023, CMS issued guidance clarifying that Medicare Advantage plans may cover obesity medications if the plan chooses to include them as a supplemental benefit. This is optional, not mandatory. Traditional Medicare Part D plans are prohibited by statute from covering weight-loss medications, but Medicare Advantage plans (which are private insurance plans that contract with CMS) have flexibility to add benefits beyond traditional Medicare.

Cigna's Medicare Advantage response: as of January 2026, 41% of Cigna Medicare Advantage plans include limited coverage for Wegovy or Saxenda, according to the CMS plan finder database. The coverage is subject to prior authorization and typically requires:

• BMI above 30 or BMI above 27 with at least one obesity-related comorbidity
• Documented participation in a CMS-approved intensive behavioral therapy program (16 sessions over 6 months)
• No history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
• Cardiovascular disease or high cardiovascular risk (required for some plans following the SELECT trial data showing cardiovascular benefit with semaglutide)

The cost-sharing structure: even when covered, Medicare Advantage members typically pay 25-33% coinsurance for specialty-tier medications, which translates to $337-$445 monthly for Wegovy. Some plans cap specialty drug costs at $500 per month, which provides partial protection against price increases.

Why this matters for commercial plan members: the Medicare Advantage coverage decisions signal where commercial plans may move in 2027-2028. Employers watch Medicare Advantage trends closely because MA plans serve as a testing ground for benefit design changes. If MA plans demonstrate that obesity drug coverage reduces long-term medical costs (fewer diabetes diagnoses, fewer cardiovascular events), commercial plans may add the obesity rider more widely. If the costs exceed the savings, commercial plans will continue to exclude obesity medications.

The early data is mixed. A 2025 analysis by the Peterson-KFF Health System Tracker found that Medicare Advantage members using GLP-1s had 12% lower hospitalization rates over 24 months compared to matched controls, but the medication cost was $16,200 per member over the same period, which exceeded the hospitalization savings by a factor of 2.3 (Peterson-KFF Health System Tracker, 2025). The ROI calculation depends heavily on the time horizon. Over 5-10 years, the cardiovascular and diabetes prevention benefits may justify the cost. Over 2-3 years, they do not.

Decision tree: your coverage pathway based on plan type

If you have a Cigna commercial plan (employer-sponsored or individual marketplace):

1. Check your plan documents for an obesity benefit rider. Log into myCigna.com, navigate to "Coverage" > "Medical Benefits," and search for "obesity" or "weight management." If the rider is listed, you have coverage for Wegovy and Saxenda with prior authorization. If it is not listed, you do not.

1. If you have type 2 diabetes (A1C above 6.5%), ask your provider to submit a prior authorization for Ozempic or Mounjaro using diagnosis code E11.9. Include documented A1C, failed metformin trial, and BMI. Approval probability: 89%.

1. If you have prediabetes (A1C 5.7-6.4%) or obesity without diabetes, ask your provider whether you meet criteria for a diabetes diagnosis based on current lab results. If yes, follow step 2. If no, prior authorization will likely be denied unless you have the obesity rider.

1. If prior authorization is denied and you do not want to appeal, compare retail pricing with manufacturer savings cards versus compounded semaglutide or tirzepatide. The cost difference is typically $500-$900 per month.

If you have a Cigna Medicare Advantage plan:

1. Check the CMS plan finder (medicare.gov/plan-compare) to see if your specific plan includes obesity medication coverage. Enter your plan name and contract number, then search the formulary for "semaglutide" or "Wegovy."

1. If your plan includes coverage, ask your provider to submit prior authorization with documentation of BMI, cardiovascular risk factors, and completion of (or enrollment in) an intensive behavioral therapy program.

1. If your plan does not include coverage, you cannot appeal based on medical necessity because the exclusion is written into the plan contract. Your options are to switch plans during the annual enrollment period (October 15 - December 7) or pay out-of-pocket.

If you have traditional Medicare with Part D:

Traditional Medicare Part D plans are prohibited from covering weight-loss medications by federal statute (Social Security Act Section 1860D-2). This prohibition applies even if you have diabetes. Ozempic and Mounjaro are covered for diabetes, but only when prescribed for diabetes, not for weight loss. If your provider prescribes Ozempic for obesity using diagnosis code E66.01, the claim will be denied. If your provider prescribes Ozempic for diabetes using diagnosis code E11.9, the claim will be approved.

FAQ

Does Cigna cover Ozempic for weight loss? Cigna covers Ozempic when prescribed for type 2 diabetes, not for weight loss alone. If your provider submits a prior authorization with a diabetes diagnosis code (E11.9) and documented A1C above 7.0%, approval probability is 89%. If the authorization uses an obesity diagnosis code without diabetes, it will be denied unless your plan includes the obesity benefit rider.

Does Cigna cover Wegovy? Cigna covers Wegovy only on plans that include the optional obesity benefit rider, which 6% of commercial groups elected as of 2026. If your plan does not have the rider, Wegovy is excluded from coverage regardless of BMI or medical necessity. Check your plan documents or call Cigna customer service to confirm rider status.

Does Cigna cover Mounjaro for weight loss? Cigna covers Mounjaro for type 2 diabetes with prior authorization. Off-label use for weight loss is not covered unless your plan includes the obesity rider. The approval criteria are identical to Ozempic: documented diabetes diagnosis, A1C above 7.0%, failed metformin trial, and BMI above 27.

What is the Cigna obesity benefit rider? The obesity benefit rider is an optional add-on that employers can purchase for their group health plan. It adds coverage for FDA-approved obesity medications (Wegovy, Saxenda), bariatric surgery, nutritional counseling, and behavioral therapy. The rider costs employers $52-$78 per member per month and is elected by 6% of Cigna commercial groups.

How do I know if my Cigna plan has the obesity rider? Log into myCigna.com, navigate to "Coverage" > "Medical Benefits," and search for "obesity" or "weight management." If the rider is included, you will see a section titled "Obesity Treatment" or "Weight Management Services" with details on covered medications and prior authorization requirements. If you do not see this section, your plan does not have the rider.

What are the prior authorization requirements for Ozempic on Cigna? Cigna requires nine elements: diabetes diagnosis code (E11.9), BMI above 27 with comorbidities or above 30, A1C above 7.0% within the past 180 days, failed metformin trial of at least 90 days, documented lifestyle intervention, prescriber specialty or attestation, requested dose and duration, and specialty pharmacy selection. Missing any element triggers a denial.

How long does Cigna prior authorization take? Standard prior authorizations are processed within 15 business days. Urgent requests (patient currently on therapy and out of medication) are processed within 3 business days. In practice, most approvals take 8-12 business days because incomplete submissions are routed to manual review.

Can I appeal a Cigna denial for weight-loss medication? Yes. The appeals process has three levels: peer-to-peer review (18% overturn rate), external medical review (34% overturn rate), and state insurance department complaint (61% overturn rate for denials based on incorrect application of medical necessity criteria). Appeals add 45-90 days to the approval timeline.

Does Cigna Medicare Advantage cover weight-loss injections? 41% of Cigna Medicare Advantage plans include limited coverage for Wegovy or Saxenda as of 2026. Coverage requires prior authorization, BMI above 30 or above 27 with comorbidities, completion of intensive behavioral therapy, and cardiovascular disease or high cardiovascular risk on some plans. Traditional Medicare Part D plans do not cover weight-loss medications.

How much does Ozempic cost without insurance? The retail cash price for Ozempic is $968.52 per pen (four 2 mg doses, one month supply at the maintenance dose). The manufacturer savings card reduces the cost by up to $150 per month for eligible patients, resulting in a net cost of $818.52. The savings card cannot be used with government insurance or when the medication is covered by commercial insurance.

What is compounded semaglutide and is it covered by Cigna? Compounded semaglutide is prepared by state-licensed compounding pharmacies using the same active ingredient as Ozempic and Wegovy but without FDA review of the compounded formulation. It is not covered by any Cigna plan. Patients pay out-of-pocket, typically $249-$299 per month, which is 70-85% lower than brand-name retail pricing.

Can I use a manufacturer savings card with Cigna insurance? Only if Cigna denied coverage. Manufacturer savings cards for Ozempic, Wegovy, and Mounjaro cannot be combined with insurance coverage. If Cigna approved your prior authorization but you have high cost-sharing, you cannot use the savings card to reduce your copay. The cards are valid only for cash-pay patients or patients whose insurance denied coverage.

Related guides

• Does Cigna Cover Ozempic? A 2026 Breakdown of Medical vs Weight Loss Coverage, Prior Authorization Requirements, and What to Do When Denied
• Will Cigna Cover Wegovy for Weight Loss? The 2026 Policy Breakdown and What to Do When Denied
• Does Cigna Cover Weight Loss Medication? A 2026 Policy Breakdown and Appeal Protocol
• Does Cigna Cover Tirzepatide for Weight Loss? The 2026 Policy Breakdown and Your Real Options
• Does Blue Cross Blue Shield Cover Weight Loss Injections? The Complete 2026 Policy Breakdown
• Does Cigna Cover Mounjaro? 2026 Policy Details, Prior Authorization Requirements, and What to Do When Denied

Sources

1. Cigna Medical Coverage Policy 0591: Obesity Interventions. Revised January 2026.
2. Cigna National Pharmacy Benefit Management Formulary. Updated quarterly, accessed April 2026.
3. Cigna Q4 2025 Investor Presentation. Obesity benefit rider enrollment data.
4. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384:989-1002.
5. Heinemann L et al. Pen User Error Rates in Insulin and GLP-1 Delivery Devices. Journal of Diabetes Science and Technology. 2023;17(4):892-901.
6. Peterson-KFF Health System Tracker. Medicare Advantage GLP-1 Cost and Utilization Analysis. 2025.
7. Centers for Medicare & Medicaid Services. Medicare Advantage Supplemental Benefits Guidance. December 2023.
8. FDA Guidance for Industry: Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Updated 2024.
9. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026;49(Suppl 1).
10. Novo Nordisk. Ozempic Prescribing Information. Revised 2024.
11. Eli Lilly. Mounjaro Prescribing Information. Revised 2024.
12. Social Security Act Section 1860D-2(e)(2)(A): Medicare Part D Exclusions.
13. FormBlends Internal Data: Prior Authorization Outcomes Analysis. January 2025 - March 2026. n=2,400.
14. FormBlends Patient Survey: Insurance Denial Response Patterns. January - December 2025. n=1,247.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro is a registered trademark of Eli Lilly and Company. Saxenda and Victoza are registered trademarks of Novo Nordisk A/S. Cigna is a registered trademark of Cigna Intellectual Property, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies. All references to brand-name medications and insurance companies are for educational comparison only.